Geodon (Pfizer) Drug Overview & Outlook 2018: A Dopamine (D2) and Serotonin (5-HT2) Antagonist - ResearchAndMarkets.com

May 14, 2018

DUBLIN--(BUSINESS WIRE)--May 14, 2018--The “Drug Overview: Geodon” report has been added to ResearchAndMarkets.com’s offering.

Geodon contains ziprasidone, a dopamine (D2) and serotonin (5-HT2) antagonist developed and marketed by Pfizer. Geodon initially launched in the US in 2001 for the treatment of schizophrenia. It subsequently gained approval for bipolar disorder indications in the US and EU in August 2004 and October 2005, respectively.

In March 2011, Meiji Seika Kaisha acquired exclusive rights to develop and commercialize ziprasidone in Japan, with RaQualia Pharma being eligible for developmental milestones and royalties on commercial sales. RaQualia Pharma announced in March 2015 that it had initiated a Phase III trial in Japan studying Geodon for the treatment of schizophrenia. The author believes that the companies are focusing on development for schizophrenia first before pursuing bipolar disorder.

Key Topics Covered

Drug Overview Product Profiles Geodon: Bipolar Disorder

List of Figures

Figure 1: Geodon for bipolar disorder - SWOT analysis

Figure 2: Drug assessment summary for Geodon in bipolar disorder

Figure 3: Drug assessment summary for Geodon in bipolar disorder

List of Tables

Table 1: Geodon bipolar disorder indication approvals

Table 2: Geodon drug profile

Table 3: Overview of key clinical trial data for Geodon in bipolar disorder

Table 4: Treatment-emergent adverse reactions in =5% of Geodon-treated adult patients with bipolar mania in double-blind, placebo-controlled trials

Table 5: Geodon ongoing late-phase clinical trials as a therapy in children and adolescents with bipolar I disorder

Table 6: Overview of key clinical trial data for Geodon in bipolar depression

For more information about this report visit https://www.researchandmarkets.com/research/jhf3bf/geodon_pfizer?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180514005476/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Mental Disorders Drugs,Schizophrenia Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 05/14/2018 04:57 AM/DISC: 05/14/2018 04:57 AM


Update hourly